Ventripoint Diagnostics Adds 30% After Sales Strategy Revealed3 min read


Ventripoint Diagnostics (VPT: TSXV) has been one of the most liquid stocks on the TSX Venture in 2017. The biotech company is working to improve heart analysis. Its shares exploded 29% Thursday to capture the Daily Stock Challenge Breakout award.

VentriPoint received a license from Health Canada back in early March for its new VMS-PLUS™ machine and the 4-chamber (4C) heart analysis system. Since, the company explained,

“This is an expansion of the VMS heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart. The VMS was already licensed in Canada for use for the right ventricle (RV).”

Click here to read the press release, titled Approval for World’s First Complete Heart Analysis System for 2D Ultrasound Exams Received by Ventripoint.

Ventripoint Hopes to Cash-In on Heart Analysis VMS-PLUS

 

The company is turning its focus to sales and marketing after receiving approval for its VMS-PLUS system.

The company confirmed today that,

“The VMS is approved for the analysis of the right ventricle (RV) of the heart for anyone where the cardiologist deems the information is warranted or desired in the United States, Canada and Europe. The VMS-PLUS™ has recently been approved by Health Canada for the measurement of volumes of the other 3 chambers of the heart – right atrium (RA), left ventricle (LV) and left atrium (LA).”

In this morning’s press release, focused on the sales initiative, Company CEO, Dr. George Adams, stated,

“Ventripoint has achieved a ‘world first’ with the approval of a whole-heart analysis system for 2D ultrasound exams, which provides accurate and reliable measurements equivalent to an MRI.”

Click here to read the entire press release.

Ventripoint Stalls after Epic March

 

We reacted to Ventripoint’s incredible market action earlier in the year. On March 8th, we published an article titled Ventripoint Diagnostics Rebounds after 3 Days of Declines. Below is a short excerpt:

“March 2nd, might be remembered as the best day for any stock on the TSX Venture Exchange in 2017. Ventripoint opened at $0.14, traded to a high of $0.92 before settling at $0.69 per share. The junior biotech stock traded a whopping 44.53 million shares worth nearly $20 million dollars.”

Click here to read the entire article.

On the VMS-PLUS the company has decided to focus on the Middle East and North Africa (MENA) region. Heart disease is particularly prevalent in these parts of the world. The company reported,

“For example; cardiovascular disease is responsible for one in five deaths in the United Arab Emirates (UAE) and one in four adults in Saudi Arabia are likely to have a heart attack within the next 10 years. The UAE has 70 public and private hospitals and 150 medical centres and clinics and is opening a new hospital every month. Saudi Arabia has approximately 600 hospitals and 2282 clinical centres and is expanding its healthcare system.”

 

Click here to read the entire press release.

Ventripoint Rebounds in June Stock Challenge

 

Ventripoint has had a tough couple of months, falling steadily from its high in March. After weeks of declines, Ventripoint’s shares exploded Thursday, outperforming all stocks in June’s Stock Challenge.

Pinnacle member ‘Hello‘ selected Ventripoint for June. His combined average return jumped 15.4% Thursday. Hello has won the Stock Challenge once before, but remains out of the Top 20.

With just a few days behind us in June, long-time member ‘mountaineer78’ is in 1st with a 16.96% return. There are five past Stock Challenge Champs in the Top 11.

View Top 20 Leader Board